Sac-TMT extends survival in gastroesophageal cancer, Merck says; AI predicts gastric cancer recurrence; study explains CAR T enterocolitis

A flexible endoscope with its control head and two round angulation wheels, its long insertion tube coiling in a loose loop on a table.

Merck said sacituzumab tirumotecan met its overall survival goal in the phase 3 TroFuse-015 trial in previously treated advanced gastroesophageal adenocarcinoma, OncLive reported Nov. 20.

A deep learning model in The Lancet Digital Health predicted peritoneal recurrence and immunotherapy response in gastric cancer, and a study in Nature Medicine tied enterocolitis after BCMA-directed CAR T-cell therapy to CAR T cells accumulating in the gut.

  • Research Nov 20, 2026
    Merck said sacituzumab tirumotecan produced a statistically significant improvement in overall survival, the primary end point, versus treatment of physician's choice in the phase 3 TroFuse-015 trial in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma, OncLive reported Nov. 20. The open-label trial enrolled 473 patients in the third-line or later setting and did not meet its secondary end point of progression-free survival. The topline results are company-reported and include no survival figures; Merck said the data will be presented at a future meeting and submitted to regulators.
    Source: OncLive
  • AI Nov 19, 2026
    A retrospective multicenter study published Nov. 19 in The Lancet Digital Health built a deep learning model, combining a convolutional neural network and a Transformer, as a noninvasive radiological method to predict tertiary lymphoid structures, peritoneal recurrence and survival in gastric cancer, using eight Chinese cohorts. In the training cohort, five-year peritoneal recurrence was 66.69% with low model scores versus 26.28% with high scores; the concordance index for peritoneal recurrence-free survival in that cohort was 0.654. In two immunotherapy cohorts, objective response rates were 54.5% versus 5.6% and 53.1% versus 9.7% for high versus low scores.
  • Research Nov 19, 2026
    Nine of 158 patients treated with the BCMA-directed CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel), about 5%, developed immune effector cell-associated enterocolitis, with persistent diarrhea and inflammation, according to an MD Anderson study published Nov. 19 in Nature Medicine. CAR T cells accumulated in the digestive tract and appeared to drive ongoing inflammation and damage, and long-term blood CAR T-cell persistence was more than 100 times higher on average than in patients without the condition. The authors said testing tissue for CAR-positive T cells could speed diagnosis and treatment for patients with gastrointestinal symptoms.

The weekly innovation roundup for gastroenterology, published every Sunday for the week before; every item links to its sources. Latest gastroenterology news · All specialties

Latest news

Tagged gastroenterology, from the daily briefing

  1. Interim results published from a randomized trial of surveillance colonoscopy intervals after polypectomy
  2. IDSA issues 2026 guideline on preventing invasive aspergillosis in adult solid organ transplant recipients
  3. Enterocolitis hit 3% of 1,308 cilta-cel recipients with myeloma, at a median 75 days after infusion

See all the latest news